EAU 2018

EAU 2018 - Prostate Specific Antigen (PSA) Response in Men With Nonmetastatic Castration-Resistant Prostate Cancer (M0 CRPC) Treated With Enzalutamide: Results From PROSPER

EAU 2018: Challenges in Flexible Endoscopy

Copenhagen, Denmark (UroToday.com)  Dr. Seitz started off the thematic session on “Challenges in Upper Urinary Tract Urothelial Cancer” with challenges in flexible endoscopy. Upper Urinary Tract Urothelial Carcinoma (UTUC) remains a challenge to manage due to the relative rarity of the disease, the difficulties with tissue acquisition and imaging, and difficulties with reliable staging.

EAU 2018: European Society of Urogenital Radiology Lecture: Challenges in Imaging of UTUC

Copenhagen, Denmark (UroToday.com)  Dr. Cowan was the guest speaker for the ESUR lecture and focused on challenges in the imaging of urinary tract urothelial cancer (UTUC). He broke down the challenges that face us into 3 categories: those that relate to the disease, those that related to the urologist and radiologist and those that relate to the radiologist alone.

EAU 2018: RNA Sequencing Identifies 3 Different Molecular Grades and Immune Checkpoint Cascades with Distinct Clinical Behavior in Non-Muscle Invasive Bladder Cancer

Copenhagen, Denmark (UroToday.com) Non muscle invasive bladder cancer (NMIBC), which represents 70% of newly diagnosed bladder cancer, has a highly variable clinical behavior, which is not adequately predicted by histological grade and clinical parameters. As all clinicians know, the high-grade and low-grade classification (WHO 2004 designation) is riddled with inconsistencies. We all have patients with low-grade disease who progress and those with high-grade disease who do not. Partly dependent on pathologist skill with accurately interpreting pathology slides, there is a high degree of variability in the interpretation.

EAU 2018: Case-Based Debate BRCA 1/2 Testing Before Treatment of Metastatic Castration-Resistant Prostate Cancer - Not Yet

Copenhagen, Denmark (UroToday.com) Dr. Hamdy presented is view on why it is still not the right time for genetic testing of metastatic castrate resistant prostate cancer (MCRPC) patients. There are 5 things an MCRPC patient wants to know:

EAU 2018: Case-Based Debate: BRCA 1/2 Testing Before Treatment of Metastatic Castration-Resistant Prostate Cancer - Ready for Prime Time

Copenhagen, Denmark (UroToday.com) Dr. Nelson gave an overview of why BRCA 1 and 2 testing should be done before treatment of metastatic castrate resistant prostate cancer (MCRPC) patients.  His talk summarized 10 points on why it is prime time for genetic testing before treating these patients.

EAU 2018: Analysis of the Impact of Assistant Surgeon Experience on Peri‐Operative Outcomes of Robotic Partial Nephrectomy

Copenhagen, Denmark (UroToday.com) The Da-Vinci robot offers three-dimensional vision, tremor filtering, improved dexterity, increased visualization and an ergonomic setting to enhance surgeon comfort and precision. However, the surgeon is physically separated from the patient. As a result, it mandates the presence of an assistant surgeon who ensures the smooth running of the intervention. This current study aimed to investigate the impact of the assistant surgeon’s experience on peri-operative outcomes of robotic partial nephrectomy (RPN).